Viking Therapeutics, Inc. (VKTX) EPS Estimated At $-0.11; LEND LEASE CORPORATION LTD ORD ORDINARY (LLESF) SI Increased By 2.1%

April 28, 2018 - By Ellis Scott

LendLease Group Stapled Securities (OTCMKTS:LLESF) Logo

Analysts expect Viking Therapeutics, Inc. (NASDAQ:VKTX) to report $-0.11 EPS on May, 9.They anticipate $0.12 EPS change or 52.17% from last quarter’s $-0.23 EPS. After having $-0.14 EPS previously, Viking Therapeutics, Inc.’s analysts see -21.43% EPS growth. The stock increased 2.32% or $0.09 during the last trading session, reaching $3.97. About 1.09M shares traded. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 240.16% since April 28, 2017 and is uptrending. It has outperformed by 228.61% the S&P500.

LEND LEASE CORPORATION LTD ORD ORDINARY (OTCMKTS:LLESF) had an increase of 2.1% in short interest. LLESF’s SI was 812,300 shares in April as released by FINRA. Its up 2.1% from 795,600 shares previously. With 1,700 avg volume, 478 days are for LEND LEASE CORPORATION LTD ORD ORDINARY (OTCMKTS:LLESF)’s short sellers to cover LLESF’s short positions. The SI to LEND LEASE CORPORATION LTD ORD ORDINARY’s float is 0.15%. It closed at $13.65 lastly. It is down 0.00% since April 28, 2017 and is . It has underperformed by 11.55% the S&P500.

LendLease Group provides property and infrastructure solutions in Australia, Asia, Europe, and the Americas. The company has market cap of $7.91 billion. It operates through three divisions: Development, Construction, and Investments. It has a 13.15 P/E ratio. The firm is involved in the development of communities, inner city mixed use developments, and apartments, as well as retirement, retail, and commercial assets; and social and economic infrastructures.

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 13 analyst reports since April 7, 2016 according to SRatingsIntel. Maxim Group maintained the shares of VKTX in report on Thursday, August 10 with “Buy” rating. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given on Wednesday, November 29 by Roth Capital. Laidlaw maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) rating on Thursday, August 11. Laidlaw has “Buy” rating and $10 target. The stock has “Buy” rating by H.C. Wainwright on Monday, March 26. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given on Tuesday, November 21 by Roth Capital. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given on Thursday, April 7 by H.C. Wainwright. The rating was maintained by Maxim Group with “Buy” on Wednesday, July 12. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given on Tuesday, June 6 by Maxim Group. The rating was reinitiated by H.C. Wainwright with “Buy” on Friday, November 10. The company was maintained on Thursday, August 10 by H.C. Wainwright.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $202.21 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>